During the last session, Plus Therapeutics Inc (NASDAQ:PSTV)’s traded shares were 23.26 million, with the beta value of the company hitting 0.62. At the end of the trading day, the stock’s price was $0.20, reflecting an intraday loss of -34.38% or -$0.11. The 52-week high for the PSTV share is $2.31, that puts it down -1055.0 from that peak though still a striking -20.0% loss since the share price plummeted to a 52-week low of $0.24. The company’s market capitalization is $6.63M, and the average intraday trading volume over the past 10 days was 5.08 million shares, and the average trade volume was 12.82 million shares over the past three months.
Plus Therapeutics Inc (NASDAQ:PSTV) trade information
Plus Therapeutics Inc (PSTV) registered a -34.38% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -34.38% in intraday trading to $0.20, hitting a weekly high. The stock’s 5-day price performance is -38.64%, and it has moved by -39.55% in 30 days. Based on these gigs, the overall price performance for the year is -89.87%. The short interest in Plus Therapeutics Inc (NASDAQ:PSTV) is 0.51 million shares and it means that shorts have 0.14 day(s) to cover.
Plus Therapeutics Inc (PSTV) estimates and forecasts
In the rating firms’ projections, revenue will decrease -20.81% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.04M as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 1.29M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 1.28M and 1.46M respectively. In this case, analysts expect current quarter sales to shrink by -18.88% and then drop by -11.57% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 46.51%. While earnings are projected to return 62.82% in 2025, the next five years will return 49.89% per annum.
PSTV Dividends
Plus Therapeutics Inc is due to release its next quarterly earnings on 2025-May-30. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Plus Therapeutics Inc (NASDAQ:PSTV)’s Major holders
Plus Therapeutics Inc insiders own 9.29% of total outstanding shares while institutional holders control 3.90%, with the float percentage being 4.29%. AIGH CAPITAL MANAGEMENT LLC is the largest shareholder of the company, while 17.0 institutions own stock in it. As of 2024-06-30, the company held over 0.57 million shares (or 8.7478% of all shares), a total value of $0.84 million in shares.
The next largest institutional holding, with 46648.0 shares, is of GEODE CAPITAL MANAGEMENT, LLC’s that is approximately 0.7176% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $68572.0.
